Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: MSL001
MIFTS: 64

Measles

Categories: Rare diseases, Infectious diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Measles

About this section

MalaCards integrated aliases for Measles:

Name: Measles 12 76 53 55 43 3 44 15 73
Rubeola 53 3
Morbilli 12

Classifications:

MalaCards categories:
Global: Rare diseases Infectious diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:8622
ICD9CM 35 055
MeSH 44 D008457
NCIt 50 C96406
SNOMED-CT 68 14189004 154338006
UMLS 73 C0025007
Sources

Summaries for Measles

About this section
MedlinePlus : 43 Measles is an infectious disease caused by a virus. It spreads easily from person to person. It causes a blotchy red rash. The rash often starts on the head and moves down the body. Other symptoms include Fever Cough Runny nose Conjunctivitis (pink eye) Feeling achy and run down Tiny white spots inside the mouth Sometimes measles can lead to serious problems. There is no treatment for measles, but the measles-mumps-rubella (MMR) vaccine can prevent it. "German measles", also known as rubella, is a completely different illness. Centers for Disease Control and Prevention

MalaCards based summary : Measles, also known as rubeola, is related to encephalitis and hepatitis, and has symptoms including fever, cough and coryza. An important gene associated with Measles is CD46 (CD46 Molecule), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Vitamin A and BCG vaccine have been mentioned in the context of this disorder. Affiliated tissues include skin, eye and brain, and related phenotypes are hematopoietic system and cellular

Disease Ontology : 12 A viral infectious disease that results in infection located in skin, has material basis in Measles virus, which is transmitted by contact with oronasal secretions, or semen of an infected person. The infection has symptom fever, has symptom cough, has symptom coryza, has symptom conjunctivitis, and has symptom maculopapular, erythematous rash.

CDC : 3 Measles starts with fever, runny nose, cough, red eyes, and sore throat. It’s followed by a rash that spreads over the body. Measles virus is highly contagious virus and spreads through the air through coughing and sneezing. Make sure you and your child are protected with measles, mumps, and rubella (MMR) vaccine.

Wikipedia : 76 Measles is a highly contagious infectious disease caused by the measles virus. Symptoms usually develop... more...

Sources

Related Diseases for Measles

About this section

Diseases related to Measles via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 274)
# Related Disease Score Top Affiliating Genes
1 encephalitis 30.8 CD209 DDX58 TLR3
2 hepatitis 30.5 DDX58 EIF2AK2 IFNA1 IFNAR2
3 mumps 30.3 CD40LG CD46 IFNAR2 IFNG IL2 STAT1
4 stomatitis 30.2 ADAR DDX58 EIF2AK2 IFNA1
5 meningitis 30.1 CD40LG IFNG TLR2
6 newcastle disease 30.0 DDX58 IFNA1 IFNB1
7 dengue virus 30.0 CD209 DDX58 IFIH1
8 mouth disease 29.6 IFNA1 IFNG STAT1
9 central nervous system disease 29.6 CD40LG IFNB1 IFNG
10 tetanus 29.3 CD40LG IFNG IL2
11 rheumatic disease 29.3 CD40LG IFNA1 IFNG
12 west nile virus 29.1 CD209 DDX58 IFIH1 IFNA1 TLR3
13 hepatitis c virus 29.1 ADAR DDX58 EIF2AK2 IFIH1 IFNG
14 influenza 29.0 DDX58 EIF2AK2 IFIH1 IFNA1 IFNB1 IFNG
15 vaccinia 28.8 EIF2AK2 IFNA1 IFNB1 IL2
16 cutaneous t cell lymphoma 28.7 IFNA1 IFNG IL2
17 toxic shock syndrome 28.7 IFNG IL2 TLR2
18 multiple sclerosis 28.5 IFNA1 IFNB1 IFNG IL2 STAT1
19 herpes simplex 28.5 CD209 DDX58 EIF2AK2 IFIH1 IFNA1 IFNB1
20 hepatitis c 27.9 DDX58 EIF2AK2 IFNA1 IFNAR2 IFNB1 IFNG
21 human immunodeficiency virus type 1 27.3 ADAR CD209 IFNA1 IFNG IL2 STAT1
22 malaria 26.5 CD40LG FCGR2B IFNG IL2 TLR2
23 rubella 12.2
24 panencephalitis, subacute sclerosing 12.0
25 primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection 11.9
26 congenital rubella 11.3
27 acute disseminated encephalomyelitis 11.3
28 striatonigral degeneration, infantile 11.1
29 acute hemorrhagic leukoencephalitis 10.8
30 infections, recurrent, with encephalopathy, hepatic dysfunction, and cardiovascular malformations 10.8
31 immunodeficiency 45 10.8
32 microcephaly 10.8
33 croup 10.8
34 immune-mediated encephalomyelitis 10.8
35 postinfectious encephalomyelitis 10.8
36 oral erosive lichen 10.8 IFNA1 IFNB1
37 marburg hemorrhagic fever 10.8 CD209 IFNB1
38 singleton-merten syndrome 10.6 DDX58 IFIH1
39 human t-cell leukemia virus type 2 10.5 ADAR IFNG STAT1
40 chronic inflammatory demyelinating polyradiculoneuropathy 10.5 IFNB1 IFNG STAT1
41 neisseria meningitidis infection 10.5 CD46 MSN TLR2
42 fanconi anemia, complementation group c 10.4 EIF2AK2 IFNA1 STAT1
43 axillary adenitis 10.4 CD40LG STAT1
44 microphthalmia with limb anomalies 10.4 IFNA1 IFNB1 STAT1
45 fasciolopsiasis 10.4 CD40LG IFNA1
46 aspergillosis 10.4 CD209 IFNG TLR2
47 aging 10.4
48 relapsing-remitting multiple sclerosis 10.3 IFNA1 IFNB1 IFNG
49 kyasanur forest disease 10.3 CD40LG IFNA1
50 extrinsic cardiomyopathy 10.3 CD40LG IFNB1 TLR3

Graphical network of the top 20 diseases related to Measles:



Diseases related to Measles
Sources

Symptoms & Phenotypes for Measles

About this section

Symptoms:

12
  • • fever
  • • cough
  • • coryza
  • • conjunctivitis
  • • maculopapular

UMLS symptoms related to Measles:


exanthema, fever, pruritus, koplik spots

MGI Mouse Phenotypes related to Measles:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.24 IFNB1 DHX58 IFNG EIF2AK2 FCGR2B ADAR
2 cellular MP:0005384 10.14 DDX58 DHX58 IFNG EIF2AK2 FCGR2B ADAR
3 homeostasis/metabolism MP:0005376 10.13 IFNB1 DHX58 IFNG FCGR2B ADAR CD40LG
4 immune system MP:0005387 10.13 IFNB1 DHX58 IFNG EIF2AK2 FCGR2B ADAR
5 mortality/aging MP:0010768 9.77 DDX58 DHX58 IFNG EIF2AK2 FCGR2B ADAR
6 liver/biliary system MP:0005370 9.76 IFNG FCGR2B ADAR IFIH1 DDX58 TLR2
7 neoplasm MP:0002006 9.28 IFNB1 IFNG EIF2AK2 DDX58 IFNAR2 TLR2
Sources

Drugs & Therapeutics for Measles

About this section

Drugs for Measles (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 122)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Not Applicable 11103-57-4, 68-26-8 445354
2
BCG vaccine Investigational Phase 4,Phase 2
3 Retinol palmitate Phase 4,Phase 3,Not Applicable
4 Micronutrients Phase 4,Phase 3,Not Applicable
5 Trace Elements Phase 4,Phase 3,Not Applicable
6 Vaccines Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
7 Vitamins Phase 4,Phase 3,Not Applicable
8 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
9 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
10 Antioxidants Phase 4,Phase 3,Not Applicable
11 Protective Agents Phase 4,Phase 3,Not Applicable
12 Adjuvants, Immunologic Phase 4
13 Heptavalent Pneumococcal Conjugate Vaccine Phase 4,Phase 3,Phase 2,Not Applicable
14 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1
15 Immunoglobulin G Phase 4,Phase 3
16 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
17 Liver Extracts Phase 4,Phase 1
18 retinol Nutraceutical Phase 4,Phase 3,Not Applicable
19
Sulfadoxine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 2447-57-6 17134
20
Pyrimethamine Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 58-14-0 4993
21
Sulfamethoxazole Approved Phase 3 723-46-6 5329
22
Tetracycline Approved, Vet_approved Phase 3,Phase 2 60-54-8 5353990
23
Iron Approved Phase 3 7439-89-6 23925
24
Hydroxocobalamin Approved Phase 3 13422-51-0 11953898 44475014
25
Trimethoprim Approved, Vet_approved Phase 3 738-70-5 5578
26
Mefloquine Approved, Investigational Phase 2, Phase 3 53230-10-7 4046
27
Proguanil Approved Phase 2, Phase 3,Not Applicable 500-92-5 4923
28
Amoxicillin Approved, Vet_approved Phase 3,Not Applicable 26787-78-0 33613
29
Tacrolimus Approved, Investigational Phase 3 104987-11-3 445643 439492
30
Dapsone Approved, Investigational Phase 2, Phase 3,Not Applicable 80-08-0 2955
31
Pimecrolimus Approved, Investigational Phase 3 137071-32-0 6447131 17753757
32
Aluminum hydroxide Approved, Investigational Phase 3,Phase 2,Phase 1 21645-51-2
33
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 143 6006
34
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 59-30-3 6037
35
Cyanocobalamin Approved, Nutraceutical Phase 3 68-19-9 44176380
36
Lactitol Investigational Phase 3,Phase 2 585-86-4 3871
37
Chlorproguanil Investigational Phase 2, Phase 3,Not Applicable 537-21-3 151170 9571037
38 Renal Agents Phase 3,Phase 2,Phase 1,Not Applicable
39 Folic Acid Antagonists Phase 3,Phase 2,Phase 1,Not Applicable
40 Anti-Bacterial Agents Phase 3,Phase 2,Not Applicable
41 Vitamin B Complex Phase 3,Phase 2,Phase 1,Not Applicable
42 Antibiotics, Antitubercular Phase 3,Phase 2
43 Fanasil, pyrimethamine drug combination Phase 3,Phase 2,Phase 1,Not Applicable
44 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Not Applicable
45 Antiparasitic Agents Phase 3,Phase 2,Phase 1,Not Applicable
46 Antiprotozoal Agents Phase 3,Phase 2,Phase 1,Not Applicable
47 Antimalarials Phase 3,Phase 2,Phase 1,Not Applicable
48 Analgesics Phase 3
49 Rho(D) Immune Globulin Phase 3,Phase 2
50 gamma-Globulins Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 250)
# Name Status NCT ID Phase Drugs
1 Additional Measles Vaccine at 4 Months of Age Unknown status NCT01486355 Phase 4
2 Trial of Additional Measles Vaccine to Reduce Child Mortality Unknown status NCT01644721 Phase 4
3 Trial of Additional Measles Vaccine to Reduce Child Mortality. Burkina Faso. Unknown status NCT01668745 Phase 4
4 The Effect on Overall Mortality of a National Policy of Limiting Measles Vaccination to Children Below 12 Months of Age Unknown status NCT01306006 Phase 4
5 The Safety and Immunogenicity Study of Rotavirus Vaccine Simultaneously Vaccinated With MR or MMR Vaccine Unknown status NCT02153866 Phase 4
6 Vitamin A Supplementation With Routine Childhood Vaccines and Mortality and Morbidity Unknown status NCT00168623 Phase 4 Vitamin A
7 Vitamin A Supplementation With Bacille Calmette Guerin (BCG) Vaccine Unknown status NCT00168610 Phase 4 Vitamin A
8 Coadministration of Measles-rubella and Rotavirus Vaccines Completed NCT01700621 Phase 4
9 Immunogenicity of Co-administration of Measles and Japanese Encephalitis Vaccines Completed NCT02643433 Phase 4
10 Search for the Measles Vaccine Virus Excretion in Breast Milk of Breastfeeding Women After Postpartum Vaccination With MMR Completed NCT02325310 Phase 4
11 Early Two-dose Measles Vaccination Trial Completed NCT00168558 Phase 4
12 Long-term Follow-up of Measles Antibodies Completed NCT00168571 Phase 4
13 Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella Vaccine Completed NCT02880865 Phase 4
14 Non-Specific Effects of Standard Titre Measles Vaccination Completed NCT00168662 Phase 4
15 Safety and Efficacy of Measles, Mumps, Rubella Vaccination in Juvenile Idiopathic Arthritis Completed NCT00731965 Phase 4
16 Immunogenicity and Safety of Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases Completed NCT00126997 Phase 4
17 Study on Immunization Schedule of Beijing Tiantan Biological's Measles-mumps-rubella(MMR) Vaccine Completed NCT03160820 Phase 4
18 Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single Dose and Multidose Presentations Completed NCT01777529 Phase 4
19 MMR Vaccination Among HIV-infected Adults Completed NCT02724852 Phase 4
20 Immunogenicity and Safety of Hepatitis A Vaccine Given at the Same Time of Measles, Mumps, Rubella Combined Vaccine Completed NCT00313950 Phase 4
21 Immunology of Non-specific Effects of Vaccine Completed NCT00168545 Phase 4
22 Randomized Study of Not Giving Diphteria-tetanus-pertussis Vaccination With or After Measles Vaccination Completed NCT00244673 Phase 4
23 Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED) Completed NCT00326183 Phase 4
24 Assess GSK Biologicals' MMR Vaccine (Priorix) When Given to Healthy Children at the Age of 12 to 18 Months in Singapore. Completed NCT00388440 Phase 4
25 Concomitant Use of Hepatitis A Vaccine With Measles, Mumps, Rubella and Varicella Vaccine and Pneumococcal 7-Valent Conjugate Vaccine in Healthy 12-Month-Old Children (V251-067) Completed NCT00312858 Phase 4
26 IPV Clinical Trial - The Gambia Completed NCT01847872 Phase 4 IPV IM Needle;IPV ID Needle;IPV IM Device;IPV ID Device
27 Immune Response to Rotavirus Vaccine After a Supplemental Dose Given at 9 Months of Age With Local EPI Vaccines in Mali Completed NCT02286895 Phase 4
28 Safety Study of a Refrigerator-stable Formulation of VARIVAX® Completed NCT00432731 Phase 4
29 Safety & Immunogenicity of MMR Vaccine by DSJI to That by Needle-Syringe in 15-18 Months Old Children Completed NCT02253407 Phase 4
30 Induction of Immunity Against Streptococcus Pneumoniae in Adults With Inflammatory Bowel Disease Completed NCT01908283 Phase 4
31 Different Doses of Vitamin A Supplementation and Male and Female Morbidity and Mortality Completed NCT00168636 Phase 4 Vitamin A
32 Study of the Influence of Vaccination in HIV Viral Load and Immunologic Responses Against HIV Completed NCT00329251 Phase 4
33 Efficacy and Safety of Vivaglobin® in Previously Untreated Patients With Primary Immunodeficiency Completed NCT00520494 Phase 4 Vivaglobin
34 Vitamin A With BCG Vaccine Completed NCT00168597 Phase 4 Vitamin A
35 Safety and Immunogenicity of Measles Vaccine, Varicella Vaccine and Hepatitis-A Vaccine Recruiting NCT03330171 Phase 4
36 Induction of Immunity Against Measles in Pediatric Liver Transplant Recipients Recruiting NCT01770119 Phase 4
37 Vaccine Campaign Effects on General Hospital Admissions and Mortality Among Children Recruiting NCT03460002 Phase 4
38 Intralesional Measles, Mumps, Rubella (MMR) Vaccine Versus Cryotherapy in Treatment of Multiple Common and Planter Warts Recruiting NCT03183765 Phase 4 Measles-Mumps-Rubella Vaccine
39 Immunogenicity of Co-administered Yellow Fever and Measles, Mumps, and Rubella (MMR) Vaccines Recruiting NCT03368495 Phase 4
40 Homeopathic Vaccine Trial Recruiting NCT02825368 Phase 4
41 Clinical Study on Combined Immune Effect of EV71 Inactivated Vaccine Recruiting NCT03519568 Phase 4
42 The Phase IVd of Inactivated Enterovirus 71 Vaccine Enrolling by invitation NCT03296410 Phase 4
43 Measles-Rubella Vaccine Immunogenicity at 6 and 9 Months of Age Not yet recruiting NCT03071575 Phase 4
44 Occupational Exposure to Human Papilloma Virus (HPV) and Prophylactic Vaccination Not yet recruiting NCT03350698 Phase 4
45 Impact of the WHO Recommended Vitamin A Supplementation at Immunisation Contacts Terminated NCT00514891 Phase 4
46 Immunogenicity and Reactogenicity of a Trivalent MMR (Trivivac) in Healthy Infants Unknown status NCT01763268 Phase 2, Phase 3
47 The Community Effectiveness of IPTi in Southern Tanzania Unknown status NCT00152204 Phase 3 Sulfadoxine-pyrimethamine used for IPTi;IPTi
48 Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and Older Completed NCT02058563 Phase 3
49 Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases Completed NCT00127010 Phase 3
50 Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases Completed NCT00127023 Phase 3

Search NIH Clinical Center for Measles

Cochrane evidence based reviews: measles

Sources

Genetic Tests for Measles

About this section
Sources

Anatomical Context for Measles

About this section

The Foundational Model of Anatomy Ontology organs/tissues related to Measles:

19
Skin

MalaCards organs/tissues related to Measles:

41
Eye, Brain, Skin, T Cells, Testes, Lung, B Cells
Sources

Publications for Measles

About this section

Articles related to Measles:

(show top 50) (show all 1563)
# Title Authors Year
1
<i>In vitro</i> measles virus infection of human lymphocyte subsets demonstrates high susceptibility and permissiveness of both naive and memory B-cells. ( 29437964 )
2018
2
Therapeutic Outcome of Intralesional Immunotherapy in Cutaneous Warts Using the Mumps, Measles, and Rubella Vaccine: A Randomized, Placebo-controlled Trial. ( 29785233 )
2018
3
Measles: what you can do. ( 29412035 )
2018
4
Absence of Measles Virus Detection from Stapes of Patients with Otosclerosis. ( 28971731 )
2018
5
Epidemiological outbreaks of measles virus in Kazakhstan during 2015. ( 29962485 )
2018
6
An oncolytic measles virus-sensitive Group 3 medulloblastoma model in immune-competent mice. ( 29912438 )
2018
7
Measles outbreak from February to August 2017 in Messina, Italy. ( 29938234 )
2018
8
Occurrence of measles in a country with elimination status: Amplifying measles infection in hospitalized children due to imported virus. ( 29447169 )
2018
9
Social capital, trust in health information, and acceptance of Measles-Rubella vaccination campaign in Tamil Nadu: A case-control study. ( 29943738 )
2018
10
Limitations of administrative data to identify measles cases in Ontario, Canada: a cautionary tale. ( 29981059 )
2018
11
Waning of measles maternal antibody in infants in measles elimination settings - A systematic literature review. ( 29398276 )
2018
12
Resurgence risk for measles, mumps and rubella in France in 2018 and 2020. ( 29945697 )
2018
13
Transmission potential of modified measles during an outbreak, Japan, Marcha89May 2018. ( 29921344 )
2018
14
Estimating the distribution of morbidity and mortality of childhood diarrhea, measles, and pneumonia by wealth group in low- and middle-income countries. ( 29970074 )
2018
15
Measles in Returning Adult Travelers. ( 29978780 )
2018
16
Prevalence of Inadequate Immunity to Measles, Mumps, Rubella, and Varicella in MLB and NBA Athletes. ( 29792776 )
2018
17
Tweeting about measles during stages of an outbreak: A semantic network approach to the framing of an emerging infectious disease. ( 29929837 )
2018
18
The neonatal anti-viral response fails to control measles virus spread in neurons despite interferon-gamma expression and a Th1-like cytokine profile. ( 29366594 )
2018
19
Public health responses during measles outbreaks in elimination settings: Strategies and challenges. ( 29932850 )
2018
20
Measles high school vaccination program, 2014-2015: online survey of parents in NSW, Australia. ( 29925088 )
2018
21
Recognizing Measles, Mumps, and Rubella in the Emergency Department. ( 29715253 )
2018
22
Polymorphisms in the Wilms Tumor Gene Are Associated With Interindividual Variations in Rubella Virus-Specific Cellular Immunity After Measles-Mumps-Rubella II Vaccination. ( 29253144 )
2018
23
Differential miRNA expression in B cells is associated with inter-individual differences in humoral immune response to measles vaccination. ( 29381765 )
2018
24
Long-term Seroprotection Rates Following One-dose Measles (9-month) and One-dose MMR Vaccination (15 months) in Indian Children. ( 29428921 )
2018
25
Immunogenicity and safety of a second dose of a measles-mumps-rubella vaccine administered to healthy participants 7A years of age or older: a phaseA III, randomized study. ( 29902133 )
2018
26
Application of a mixture model to assess the effect of measles-mumps-rubella vaccine on the mumps epidemic in children from kindergarten to early school age in Jiangsu Province, China. ( 29792546 )
2018
27
APOBEC3G-regulated host factors interfere with measles virus replication: role of REDD1 and mTORC1 inhibition. ( 29925665 )
2018
28
Immunogenicity and safety of measles-mumps-rubella vaccine delivered by disposable-syringe jet injector in India: A randomized, parallel group, non-inferiority trial. ( 29395526 )
2018
29
Measles, mumps, and rubella antibody patterns of persistence and rate of decline following the second dose of the MMR vaccine. ( 29317117 )
2018
30
Seroprevalence of antibodies to measles and rubella eight months after a vaccination campaign in the southeast of Iran. ( 29420120 )
2018
31
Good practices and challenges in addressing poliomyelitis and measles in the European Union. ( 29659793 )
2018
32
Measles: is it still a threat? ( 29970395 )
2018
33
Measles control in Australia - threats, opportunities and future needs. ( 29934234 )
2018
34
2016 measles outbreak in Japan: A report of two cases with reappraisal of histological features. ( 29352499 )
2018
35
Vaccination strategies and results for tackling the measles outbreak in CearA! State, Brazil, 2013-2015. ( 29412346 )
2018
36
Measles vaccine in the school settings: a cross-sectional study about knowledge, personal beliefs, attitudes and practices of school teachers in northern Italy. ( 29968449 )
2018
37
The optimal dose of disease-specific antibodies for post-exposure prophylaxis of measles and rubella in Australia: new guidelines recommended. ( 29865869 )
2018
38
50 Years Ago in The Journal of Pediatrics: Atypical Exanthem after Exposure to Natural Measles: Eleven Cases in Children Previously Inoculated with Killed Vaccine. ( 29389454 )
2018
39
Poor quality data challenges conclusion and decision making: timely analysis of measles confirmed and suspected cases line list in Southern Nations Nationalities and People's Region, Ethiopia. ( 29433436 )
2018
40
Measles-Rubella Supplementary Immunization Activity Readiness Assessment - India, 2017-2018. ( 29975677 )
2018
41
Measles-derived vaccines to prevent emerging viral diseases. ( 29410084 )
2018
42
Safety of live-attenuated measles-mumps-rubella and herpes zoster vaccination in multiple myeloma patients on maintenance lenalidomide or bortezomib after autologous hematopoietic cell transplantation. ( 29426830 )
2018
43
Measles Virus Persistent Infection of Human Induced Pluripotent Stem Cells. ( 29412740 )
2018
44
Use of the revised World Health Organization cluster survey methodology to classify measles-rubella vaccination campaign coverage in 47 counties in Kenya, 2016. ( 29965975 )
2018
45
Healthcare-associated Measles Following a Nationwide Outbreak in Mongolia. ( 29394341 )
2018
46
The role of extended and whole genome sequencing for tracking transmission of measles and rubella viruses: report from the Global Measles and Rubella Laboratory Network meeting, 2017. ( 29424220 )
2018
47
Assessment of Humoral Immunity to Hepatitis B, Measles, Rubella, and Mumps in Children After Chemotherapy. ( 29309372 )
2018
48
Revaccination with Measles-mumps-rubella Vaccine and Infectious Disease Morbidity: A Danish Register-based Cohort Study. ( 29846533 )
2018
49
Measles and Rubella Global Strategic Plan 2012-2020 midterm review. ( 29307367 )
2018
50
An Eigenspace approach for detecting multiple space-time disease clusters: Application to measles hotspots detection in Khyber-Pakhtunkhwa, Pakistan. ( 29920540 )
2018
Sources

Variations for Measles

About this section
Sources

Expression for Measles

About this section
Search GEO for disease gene expression data for Measles.
Sources

Pathways for Measles

About this section

Pathways related to Measles according to GeneCards Suite gene sharing:

(show all 39)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 66
Show member pathways
 13.89 ADAR CD209 CD40LG CD46 DDX58 DHX58
2
Cytokine Signaling in Immune system 66
Show member pathways
 13.35 ADAR CD40LG DDX58 EIF2AK2 IFNA1 IFNAR2
3
Toll-like Receptor Signaling Pathway 37 1
Show member pathways
 13.02 IFNA1 IFNAR2 IFNB1 IFNG IL2 STAT1
4
PI3K-Akt signaling pathway 37
Show member pathways
 12.99 EIF2AK2 IFNA1 IFNAR2 IFNB1 IL2 STAT1
5
Allograft rejection 1 37
Show member pathways
 12.85 CD40LG IFNA1 IFNAR2 IFNG IL2 STAT1
6
Pathways in cancer 37
12.79 IFNA1 IFNAR2 IFNG IL2 STAT1
7
IL-2 Pathway 64
Show member pathways
 12.76 FCGR2B IFNG IL2 TLR2 TLR3
8
RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways 66
Show member pathways
 12.74 ADAR DDX58 DHX58 IFIH1 IFNA1 IFNB1
9
NF-KappaB Family Pathway 64
Show member pathways
 12.67 CD40LG EIF2AK2 IL2 TLR2 TLR3
10
Regulation of IFNA signaling 66
Show member pathways
 12.65 ADAR IFNA1 IFNAR2 IFNB1 IFNG IL2
11
Interferon gamma signaling 66
Show member pathways
 12.53 ADAR DDX58 EIF2AK2 IFNA1 IFNAR2 IFNB1
12
Immune response Role of DAP12 receptors in NK cells 22
Show member pathways
 12.5 IFNA1 IFNAR2 IFNB1 IFNG IL2
13
Th17 cell differentiation 37
Show member pathways
 12.4 IFNG IL2 STAT1 TLR2
14
Kaposi's sarcoma-associated herpesvirus infection 37
Show member pathways
 12.33 DDX58 EIF2AK2 IFIH1 IFNA1 IFNAR2 IFNB1
15
Type I Interferon Signaling Pathways 65
Show member pathways
 12.3 IFNA1 IFNAR2 IFNB1 IFNG STAT1
16
Th1 Differentiation Pathway 65
Show member pathways
 12.26 IFNG IL2 STAT1 TLR2 TLR3
17
Tuberculosis 37
12.25 CD209 FCGR2B IFNA1 IFNB1 IFNG STAT1
18
Influenza A 37
Show member pathways
 12.24 ADAR CD209 CD46 DDX58 EIF2AK2 FCGR2B
19
Toxoplasmosis 37
Show member pathways
 12.22 CD40LG IFNG STAT1 TLR2
20
NF-kappaB Signaling 4
12.21 CD40LG CD46 DDX58 DHX58 IFIH1 IFNA1
21
Necroptosis 37
Show member pathways
 12.19 EIF2AK2 IFNA1 IFNAR2 IFNB1 IFNG STAT1
22
Bacterial infections in CF airways 22
Show member pathways
 12.16 IFNB1 IFNG STAT1 TLR2
23
Colorectal Cancer Metastasis 64
12.16 IFNG STAT1 TLR2 TLR3
24
Osteoclast differentiation 37
12.08 FCGR2B IFNAR2 IFNB1 IFNG STAT1
25
MAPK Pathway 72
Show member pathways
 12.01 IL2 STAT1 TLR2 TLR3
26
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 65
11.97 CD209 IFNG IL2 SLAMF1
27
Jak-Stat Signaling Pathway 67
11.92 IFNA1 IFNAR2 IFNB1 IFNG IL2 STAT1
28
Hepatitis C 37
11.92 DDX58 EIF2AK2 IFNA1 IFNAR2 IFNB1 STAT1
29
Dendritic Cells Developmental Lineage Pathway 65
11.79 CD209 IFNB1 IFNG IL2 SLAMF1
30
Glucocorticoid receptor regulatory network 1
11.76 IFNG IL2 STAT1
31
Calcineurin-regulated NFAT-dependent transcription in lymphocytes 1
Show member pathways
 11.72 CD40LG IFNG IL2
32
Regulation of Telomerase 1
11.66 IFNAR2 IFNG IL2
33
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.63 CD40LG IFNG IL2
34
Downstream signaling in naive CD8+ T cells 1
Show member pathways
 11.62 IFNAR2 IFNG IL2
35
Malaria 37
11.5 CD40LG IFNG TLR2
36
Type II interferon signaling (IFNG) 1
11.42 EIF2AK2 IFNB1 IFNG STAT1
37
Inflammatory Response Pathway 1
11.31 CD40LG IFNG IL2
38
Cytokines and Inflammatory Response 1
11.25 IFNB1 IFNG IL2
39
Peginterferon alpha-2a/Peginterferon alpha-2b Pathway (Hepatocyte), Pharmacodynamics 61
Show member pathways
 11.08 ADAR DDX58 EIF2AK2 IFNAR2 STAT1
Sources

GO Terms for Measles

About this section

Cellular components related to Measles according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.61 CD209 CD40LG IFNA1 IFNAR2 IFNB1 IFNG
2 cell surface GO:0009986 9.17 CD209 CD40LG CD46 MSN SLAMF1 TLR2

Biological processes related to Measles according to GeneCards Suite gene sharing:

(show top 50) (show all 55)
# Name GO ID Score Top Affiliating Genes
1 defense response GO:0006952 9.97 FCGR2B IFNA1 IFNB1 TLR3
2 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.96 CD40LG EIF2AK2 TLR2 TLR3
3 adaptive immune response GO:0002250 9.95 CD209 CD46 IFNA1 IFNB1 IFNG IL2
4 viral entry into host cell GO:0046718 9.9 CD209 CD46 NECTIN4 SLAMF1
5 innate immune response GO:0045087 9.9 ADAR CD209 CD46 DDX58 DHX58 EIF2AK2
6 positive regulation of inflammatory response GO:0050729 9.87 IL2 TLR2 TLR3
7 B cell differentiation GO:0030183 9.87 CD40LG IFNA1 IFNB1
8 positive regulation of JNK cascade GO:0046330 9.87 FCGR2B SLAMF1 TLR3
9 humoral immune response GO:0006959 9.86 IFNA1 IFNB1 IFNG
10 positive regulation of T cell proliferation GO:0042102 9.86 CD209 CD40LG CD46 IL2
11 positive regulation of interleukin-6 production GO:0032755 9.85 DDX58 TLR2 TLR3
12 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.85 EIF2AK2 TLR2 TLR3
13 negative regulation of viral genome replication GO:0045071 9.84 ADAR EIF2AK2 IFNB1
14 response to exogenous dsRNA GO:0043330 9.83 DDX58 IFNA1 IFNB1 TLR3
15 type I interferon signaling pathway GO:0060337 9.83 ADAR IFNA1 IFNAR2 IFNB1 STAT1
16 negative regulation of type I interferon production GO:0032480 9.82 DDX58 DHX58 IFIH1
17 B cell proliferation GO:0042100 9.81 CD40LG IFNA1 IFNB1
18 positive regulation of interleukin-8 production GO:0032757 9.81 DDX58 TLR2 TLR3
19 leukocyte cell-cell adhesion GO:0007159 9.8 CD209 CD40LG MSN
20 regulation of type I interferon-mediated signaling pathway GO:0060338 9.8 IFNA1 IFNAR2 IFNB1 STAT1
21 positive regulation of interleukin-10 production GO:0032733 9.78 CD40LG CD46 TLR2
22 positive regulation of interferon-beta production GO:0032728 9.78 DDX58 IFIH1 TLR2 TLR3
23 positive regulation of peptidyl-serine phosphorylation of STAT protein GO:0033141 9.77 IFNA1 IFNB1 IFNG
24 positive regulation of chemokine production GO:0032722 9.76 EIF2AK2 TLR2 TLR3
25 positive regulation of interleukin-12 production GO:0032735 9.76 CD40LG IFNG TLR2 TLR3
26 cellular response to interferon-beta GO:0035458 9.74 IFNB1 STAT1 TLR3
27 regulation of regulatory T cell differentiation GO:0045589 9.72 IFNG IL2
28 regulation of innate immune response GO:0045088 9.72 DHX58 FCGR2B
29 positive regulation of interferon-alpha production GO:0032727 9.72 DDX58 IFIH1 STAT1
30 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.71 STAT1 TLR2
31 microglial cell activation GO:0001774 9.71 TLR2 TLR3
32 regulation of interferon-gamma-mediated signaling pathway GO:0060334 9.71 IFNG STAT1
33 negative regulation of phagocytosis GO:0050765 9.71 FCGR2B TLR2
34 positive regulation of tumor necrosis factor secretion GO:1904469 9.71 DDX58 IFIH1
35 response to interferon-alpha GO:0035455 9.71 ADAR EIF2AK2 IFNAR2
36 I-kappaB phosphorylation GO:0007252 9.7 TLR2 TLR3
37 positive regulation of regulatory T cell differentiation GO:0045591 9.7 CD46 IL2
38 response to interferon-beta GO:0035456 9.69 IFNAR2 STAT1
39 detection of virus GO:0009597 9.69 DDX58 IFIH1 TLR3
40 positive regulation of interferon-alpha secretion GO:1902741 9.68 DDX58 IFIH1
41 positive regulation of response to cytokine stimulus GO:0060760 9.68 DDX58 IFIH1
42 positive regulation of interferon-beta secretion GO:0035549 9.67 DDX58 IFIH1
43 cellular response to exogenous dsRNA GO:0071360 9.67 DDX58 IFIH1 IFNB1 TLR3
44 positive regulation of toll-like receptor signaling pathway GO:0034123 9.66 TLR2 TLR3
45 interleukin-10 production GO:0032613 9.64 CD46 TLR2
46 regulation of type III interferon production GO:0034344 9.62 DDX58 IFIH1
47 cytoplasmic pattern recognition receptor signaling pathway in response to virus GO:0039528 9.62 DDX58 IFIH1
48 response to virus GO:0009615 9.61 ADAR DDX58 DHX58 EIF2AK2 IFIH1 IFNAR2
49 defense response to virus GO:0051607 9.36 ADAR DDX58 DHX58 EIF2AK2 IFIH1 IFNA1
50 immune response GO:0006955 10.1 CD40LG FCGR2B IFNG IL2 TLR2

Molecular functions related to Measles according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.91 DDX58 EIF2AK2 IFIH1 NECTIN4 SLAMF1 STAT1
2 cytokine activity GO:0005125 9.55 CD40LG IFNA1 IFNB1 IFNG IL2
3 single-stranded RNA binding GO:0003727 9.5 DDX58 DHX58 IFIH1
4 type I interferon receptor binding GO:0005132 9.4 IFNA1 IFNB1
5 virus receptor activity GO:0001618 9.26 CD209 CD46 NECTIN4 SLAMF1
6 double-stranded RNA binding GO:0003725 9.1 DDX58 DHX58 EIF2AK2 IFIH1 MSN TLR3
7 protein binding GO:0005515 10.21 ADAR CD209 CD40LG CD46 DDX58 DHX58
Sources

Sources for Measles

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....